Drug · CHEMBL1002
LEVOSALBUTAMOL
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. LEVOSALBUTAMOL. Drugs and targets, record CHEMBL1002. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1002
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ADRB2 | Beta-2 adrenergic receptor | Beta-2 adrenergic receptor agonist | AGONIST | https://conductscience.org/library/genes/154 |
Source ChEMBL
Diseases5
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| asthma | Approval | TTD | 18 | 17 | https://conductscience.org/library/drugs?q=MONDO_0004979 |
| chronic obstructive pulmonary disease | Phase 3 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0005002 |
| discoid lupus erythematosus | Phase 2 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0019558 |
| systemic lupus erythematosus | Phase 2 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0007915 |
| bronchoconstriction | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=EFO_0009836 |
Source Open Targets
Trials35
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00809757 | A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma | Phase 3 | 197 | 2014-07-28 | levalbuterol | Its name | ClinicalTrials.gov |
| NCT00583778 | A Comparison of Levalbuterol Plus Ipratropium With Levalbuterol Alone in the Treatment of Acute Asthma Exacerbation | 141 | 2022-05-16 | levalbuterol | Its name | ClinicalTrials.gov | |
| NCT00585039 | Albuterol Versus Xopenex in Treatment of Acute Asthma in the Emergency Department (ED) | Phase 4 | 101 | 2011-08-16 | levalbuterol | Its name | ClinicalTrials.gov |
| NCT01151579 | Effect of Nebulized Bronchodilators on Heart Rate | Phase 4 | 89 | 2015-10-23 | levalbuterol | Its name | ClinicalTrials.gov |
| NCT00124176 | Continuous Levalbuterol for Treatment of Status Asthmaticus in Children | Phase 4 | 81 | 2013-03-14 | levalbuterol | Its name | ClinicalTrials.gov |
| NCT01833026 | COPD Assessment and Management Bundle Versus Usual Care | 56 | 2019-12-24 | levalbuterol | Its name | ClinicalTrials.gov | |
| NCT00583947 | A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects | Phase 2 | 53 | 2010-02-08 | levalbuterol | Its name | ClinicalTrials.gov |
| NCT02802111 | Change in Oxygen Consumption Following Inhalation Beta Agonists in Healthy Adults | 24 | 2020-10-28 | levalbuterol | Its name | ClinicalTrials.gov | |
| NCT02170532 | Aerosolized Beta-Agonist Isomers in Asthma | Phase 4 | 10 | 2014-08-04 | levalbuterol | Its name | ClinicalTrials.gov |
| NCT00819637 | A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients | Phase 4 | 2 | 2010-06-29 | levalbuterol | Its name | ClinicalTrials.gov |
1 to 10 of 35
See all 35 trialsComparisons in its trials11
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Levalbuterol vs Levalbuterol Plus Ipratropium: Number of Participants With Bronchodilation | 74 of 141 | 67 of 141 | 282 | NCT00583778 | Trial comparisons |
| Levalbuterol vs Levalbuterol Plus Ipratropium: deaths from any cause | 0 of 74 | 0 of 67 | 141 | NCT00583778 | Trial comparisons |
| Levalbuterol vs Levalbuterol Plus Ipratropium: serious adverse events | 0 of 74 | 0 of 67 | 141 | NCT00583778 | Trial comparisons |
| Levalbuterol (Xopenex) vs Albuterol: serious adverse events | 0 of 57 | 0 of 44 | 101 | NCT00585039 | Trial comparisons |
| Nebulized Albuterol 2.5mg vs Levalbuterol 1.25: serious adverse events | 2 of 58 | 3 of 31 | 89 | NCT01151579 | Trial comparisons |
| Continuous Levalbuterol (R) Nebulized Solution vs Continuous Racemic (R+S) Albuterol: serious adverse events | 0 of 40 | 0 of 41 | 81 | NCT00124176 | Trial comparisons |
| Nebulized Albuterol 2.5mg vs Levalbuterol 1.25: Total Number of Participants With Arrhythmias | 2 of 46 | 3 of 24 | 70 | NCT01151579 | Trial comparisons |
| COPD Assessment and Management Recommendations vs Usual Care: Number of Participants With Accurate Classification of Irreversible Airflow Obstruction | 10 of 34 | 5 of 22 | 56 | NCT01833026 | Trial comparisons |
| COPD Assessment and Management Recommendations vs Usual Care: serious adverse events | 0 of 34 | 0 of 22 | 56 | NCT01833026 | Trial comparisons |
| Albuterol 5 mg First, Then Levalbuterol 2.5 mg vs Levalbuterol 2.5 mg First, Then Albuterol 5 mg: deaths from any cause | 0 of 12 | 0 of 12 | 24 | NCT02802111 | Trial comparisons |
1 to 10 of 11
See all 11 comparisons in its trialsPapers from its trials5
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1002
GET https://conductscience.org/api/drugs/v1/CHEMBL1002/trials?page=2